Related Experiment Videos
High-dose intravenous gamma-globulin therapy in Kawasaki disease
Insights
High-dose intravenous gamma-globulin and aspirin therapy significantly reduce coronary aneurysms in Kawasaki disease. Even delayed treatment with gamma-globulin can lower the incidence of giant coronary aneurysms.
Area of Science:
- Pediatrics
- Cardiology
- Immunology
Background:
- Kawasaki disease is a leading cause of acquired heart disease in children.
- Coronary artery aneurysms are a significant complication, increasing the risk of myocardial infarction and sudden death.
- Early diagnosis and treatment are crucial to prevent cardiovascular sequelae.
Purpose of the Study:
- To evaluate the efficacy of different treatment regimens for preventing coronary artery aneurysms in children with Kawasaki disease.
- To compare the effectiveness of varying doses of intravenous gamma-globulin (IVIG) combined with aspirin versus aspirin alone and no treatment.
- To assess the impact of treatment timing on the development of coronary aneurysms and giant coronary aneurysms.
Main Methods:
- A retrospective study conducted in Taiwan from 1984 to 1988 involving 106 children diagnosed with Kawasaki disease.
- Patients were divided into four groups receiving different treatments: low-dose IVIG with aspirin, high-dose IVIG with aspirin, aspirin alone, and no treatment.
- Coronary artery aneurysms were assessed using two-dimensional echocardiography and aortography within 4 weeks and during a follow-up period of approximately 11.4 months.
Main Results:
- The incidence of coronary aneurysms within 4 weeks was 42.9% (low-dose IVIG), 49.0% (high-dose IVIG), 44.2% (aspirin alone), and 16.7% (no treatment).
- During follow-up, aneurysm rates were 28.6%, 18.4%, 16.4%, and 16.7% for the respective groups.
- High-dose IVIG and aspirin therapy significantly reduced coronary aneurysm incidence (p < 0.005). Giant coronary aneurysm incidence was significantly lower with high-dose IVIG and aspirin therapy (p < 0.05), with rates of 28.6%, 2.0%, 4.7%, and 14.3% respectively.
Conclusions:
- High-dose intravenous gamma-globulin therapy, even when initiated with some delay, is effective in reducing the formation of coronary artery aneurysms, particularly giant aneurysms.
- Aspirin therapy alone also showed a significant reduction in coronary aneurysm incidence.
- The study highlights the importance of prompt and appropriate treatment for Kawasaki disease to mitigate long-term cardiovascular risks.
Abstract:
The efficacy for reduction of coronary aneurysm in Kawasaki disease was studied from 1984 to 1988 in Taiwan. One hundred and six children with Kawasaki disease were treated by one of the following regimens: regimen I: aspirin and 130-200 mg/kg/day of intravenous gamma-globulin (group I = 7), regimen II: 201-400 mg/kg/day of intravenous gamma-globulin with aspirin (group II = 49) and regimen III: aspirin alone (group III = 43) and no treatment (group IV = 7). By using two-dimensional echocardiography and aortography, the coronary arterial aneurysms noted in group I, II, III and IV were 42.9%, 49.0%, 44.2% and 16.7% respectively within 4 weeks of the illness and were 28.6%, 18.4%, 16.4% and 16.7% respectively during the follow-up period of 11.4 +/- 8.2 months. The incidence of coronary aneurysm was reduced significantly (p less than 0.005) in patients with high-dose gamma-globulin therapy and with aspirin therapy alone. However, there was no difference between group II and III, probably due to delays in the time of start of prophylactic gamma-globulin therapy. There was also significant lower incidence of the giant coronary aneurysm in children with high dose gamma-globulin therapy and with aspirin therapy. (p less than 0.05) The incidences of giant aneurysm in groups I, II, III and IV were 28.6%, 2.0%, 4.7% and 14.3% respectively. These results suggest that even with delay in the time of start of prophylactic gamma-globulin therapy, it still can reduce the formation of giant coronary aneurysm.